 |
| Ticagrelor Market |
Ticagrelor is an oral antiplatelet drug which is used to reduce the risk of thrombotic cardiovascular events such as heart attacks and strokes in patients with acute coronary syndrome or a history of myocardial infarction. It inhibits the P2Y12 receptor, thereby preventing platelets from sticking together and forming clots. The drug is commonly prescribed after a heart attack or placement of a drug-eluting stent to reduce the chance of subsequent clots forming in patients who have increased risk for cardiovascular events. Ticagrelor has demonstrated effectiveness compared to clopidogrel in reducing cardiovascular events in multiple clinical studies.
The global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period
of 2024 to 2031.
Key Takeaways
Key players operating in the Ticagrelor
Market Demand are Atlas Roofing Corporation, BASF SE, Johns Manville,
Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG,
Standard Industries Inc., and The Dow Chemical Company.
Growing prevalence of cardiovascular diseases and increasing demand for
effective antiplatelet drugs post procedures such as angioplasty and stenting
are expected to create significant growth opportunities for players in the
global ticagrelor market.
Key players are focusing on expanding their product portfolio andglobal
footprint through partnerships and acquisitions. For instance, in 2021, The
Medicines Company was acquired by Novartis to expedite development and
commercialization of ticagrelor.
Market Drivers
Rising geriatric population globally which is at a higher risk of developing
cardiovascular diseases is a major factor driving the ticagrelor market growth.
Growing burden of diseases like diabetes and obesity which are contributors
to cardiovascular conditions is anticipated to propel the demand for
antiplatelet drugs like ticagrelor over the forecast period.
Market Restraints
Stringent regulatory framework for approval of new drug applications may
hamper market growth.
Bleeding risks associated with ticagrelor limits its usage in certain patient
groups.
Segment Analysis
The ticagrelor market is dominated by the acute coronary syndromes (ACS) sub
segment. Ticagrelor is primarily used for treating patients with ACS which includes
myocardial infarction and unstable angina. According to statistics, around 6
million people suffer from ACS annually in the US alone. Ticagrelor offers
improved efficacy over clopidogrel in ACS patients by reducing rate of
cardiovascular events such as heart attacks and strokes. The drug significantly
lowers mortality and morbidity in ACS patients undergoing Percutaneous Coronary
Intervention (PCI) making it the preferred antiplatelet agent over clopidogrel
in such cases. This large patient pool and enhanced efficacy over alternatives
drives the growth of the ACS sub segment of the ticagrelor market.
Global Analysis
The North America region currently dominates the ticagrelor market and is
expected to continue its lead during the forecast period. Higher awareness
about advanced treatment options for cardiovascular conditions and large
healthcare expenditure fuel the adoption of novel drugs like ticagrelor in the
region. Additionally, presence of major market players in the US contributes to
the large share held by North America. However, the Asia Pacific region is
anticipated to showcase the fastest growth in the coming years attributed to
increasing incidence of heart diseases, improving access to healthcare
facilities and growing healthcare spending in developing countries of China and
India. Rising medical tourism in Asia Pacific for cardiac procedures like
angioplasty is further expected to drive the usage of ticagrelor in the region.
Get more
insights on Ticagrelor
Market
Comments
Post a Comment